Results 31 to 40 of about 100,010 (342)

A RAGE-Targeted Antibody-Drug Conjugate: Surface Plasmon Resonance as a Platform for Accelerating Effective ADC Design and Development

open access: yesAntibodies, 2019
Antibodies, antibody-like molecules, and therapeutics incorporating antibodies as a targeting moiety, such as antibody-drug conjugates, offer significant potential for the development of highly efficacious drugs against a wide range of disorders. Despite
Gareth D. Healey   +4 more
doaj   +1 more source

Improved translation of stability for conjugated antibodies using an in vitro whole blood assay

open access: yesmAbs, 2020
For antibody-drug conjugates to be efficacious and safe, they must be stable in circulation to carry the payload to the site of the targeted cell. Several components of a drug-conjugated antibody are known to influence stability: 1) the site of drug ...
Aimee Fourie-O’Donohue   +15 more
doaj   +1 more source

Antibody–Biopolymer Conjugates in Oncology: A Review

open access: yesMolecules, 2023
Cancer is one of the most prevalent diseases and affects a large proportion of the population worldwide. Conventional treatments in the management include chemotherapy, radiotherapy, and surgery.
Vivek P. Chavda   +5 more
doaj   +1 more source

Clinical Pharmacology of Antibody-Drug Conjugates

open access: yesAntibodies, 2021
Antibody-drug conjugates (ADCs) are biopharmaceutical products where a monoclonal antibody is linked to a biologically active drug (a small molecule) forming a conjugate.
Iftekhar Mahmood
doaj   +1 more source

An Immunosuppressive Antibody–Drug Conjugate [PDF]

open access: yesJournal of the American Chemical Society, 2015
We have developed a novel antibody-drug conjugate (ADC) that can selectively deliver the Lck inhibitor dasatinib to human T lymphocytes. This ADC is based on a humanized antibody that selectively binds with high affinity to CXCR4, an antigen that is selectively expressed on hematopoietic cells.
Wang, Rongsheng E   +13 more
openaire   +4 more sources

Non-internalising antibody–drug conjugates

open access: yesChemical Society Reviews, 2022
This review introduces non-internalising Antibody–Drug Conjugates (ADCs), highlighting the linker chemistry that enables extracellular payload release.
Nicola Ashman   +2 more
openaire   +2 more sources

Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer. [PDF]

open access: yes, 2017
INTRODUCTION: Colorectal cancer remains the second leading cause of cancer death in the United States, and new strategies to prevent, detect, and treat the disease are needed.
Aka, Allison A.   +5 more
core   +2 more sources

Nanotechnology and cancer [PDF]

open access: yes, 2008
The biological picture of cancer is rapidly advancing from models built from phenomenological descriptions to network models derived from systems biology, which can capture the evolving pathophysiology of the disease at the molecular level.
Davis, Mark E., Heath, James R.
core   +2 more sources

Biological properties of adriamycin bound to biodegradable polymeric carriers [PDF]

open access: yes, 1993
Three different conjugates having adriamycin (ADR) bound to the side chain carboxyl groups of high-molecular weight poly (¿--glutamic acid) (PGA) either directly or by interpolation of GlyGly and GlyGlyGlyLeu spacers, respectively, were compared with ...
Bhakoo, M.   +8 more
core   +3 more sources

The Proteasomal Deubiquitinating Enzyme PSMD14 Regulates Macroautophagy by Controlling Golgi-to-ER Retrograde Transport [PDF]

open access: yes, 2020
Ubiquitination regulates several biological processes, however the role of specific members of the ubiquitinome on intracellular membrane trafficking is not yet fully understood.
Arias-Muñoz, Eloisa   +16 more
core   +2 more sources

Home - About - Disclaimer - Privacy